Sun Pharma's stock price increased after its acquisition of Checkpoint Therapeutics which added PD-L1 inhibitors and biotech oncology products that strengthened their immunotherapy line.

Sun Pharma shares increased by 2.76% with the market value hitting Rs 1,655.95 per share after ICICI Securities upgraded their rating from 'hold' to 'buy.' ICICI Securities evaluated the Sun Pharma stock with 31 times estimated earnings per share for FY 2027 and assigned a target price of Rs 1,895 to it. The share value declined by 10% over two months until now.

Additional brokerages such as Motilal Oswal and HDFC Securities kept their 'buy' recommendations while anticipating Sun Pharma stock to reach Rs 1,970. The brokerage firm Incred maintains its Hold recommendation while setting a target price of Rs 1,900 for the stock.

Sun Pharma strengthened their medical specialty segment through their acquisition of US-based biotech company Checkpoint Therapeutics during recent months. Sun Pharma will pay $4.1 per share in cash simultaneously resulting in $355 million up front while possible further payments worth $0.7 per share become available. Sun Pharma plans to finalize this acquisition during the second part of 2025 which will boost its capabilities in oncology and immunotherapy fields.

Sun Pharma extended its onco-derma portfolio by entering the PD-L1 inhibitor segment that enables effective treatment of different cancers with minimized adverse effects. The lifecycle of recent business acquisitions at Sun Pharma includes its 2023 Concert Pharma deal along with the 2024 Philogen collaboration which confirmed its market dominance in biotechnology.